Did Changing Sentiment Drive FarmaForce’s (ASX:FFC) Share Price Down A Worrying 56%?
If you are building a properly diversified stock portfolio, the chances are some of your picks will perform badly. But the last three years have been particularly tough on longer term FarmaForce Limited (ASX:FFC) shareholders. So they might be feeling emotional about the 56% share price collapse, in that time. The more recent news is of little comfort, with the share price down 29% in a year. More recently, the share price has dropped a further 45% in a month. But this could be related to poor market conditions — stocks are down 23% in the same time.
View our latest analysis for FarmaForce
Given that FarmaForce didn’t make a profit in the last twelve months, we’ll focus on revenue growth to form a quick view of its business development. Shareholders of unprofitable companies usually expect strong revenue growth. As you can imagine, fast revenue growth, when maintained, often leads to fast profit growth.
In the last three years, FarmaForce saw its revenue grow by 48% per year, compound. That is faster than most pre-profit companies. In contrast, the share price is down 24% compound, over three years – disappointing by most standards. It seems likely that the market is worried about the continual losses. When we see revenue growth, paired with a falling share price, we can’t help wonder if there is an opportunity for those who are willing to dig deeper.
The graphic below depicts how earnings and revenue have changed over time (unveil the exact values by clicking on the image).
ASX:FFC Income Statement, March 16th 2020
We’re pleased to report that the CEO is remunerated more modestly than most CEOs at similarly capitalized companies. It’s always worth keeping an eye on CEO pay, but a more important question is whether the company will grow earnings throughout the years. This free interactive report on FarmaForce’s earnings, revenue and cash flow is a great place to start, if you want to investigate the stock further.
A Different Perspective
The last twelve months weren’t great for FarmaForce shares, which performed worse than the market, costing holders 29%. Meanwhile, the broader market slid about 7.8%, likely weighing on the stock. The three-year loss of 24% per year isn’t as bad as the last twelve months, suggesting that the company has not been able to convince the market it has solved its problems. We would be wary of buying into a company with unsolved problems, although some investors will buy into struggling stocks if they believe the price is sufficiently attractive. While it is well worth considering the different impacts that market conditions can have on the share price, there are other factors that are even more important. Take risks, for example – FarmaForce has 4 warning signs (and 3 which are concerning) we think you should know about.
We will like FarmaForce better if we see some big insider buys. While we wait, check out this free list of growing companies with considerable, recent, insider buying.
Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on AU exchanges.
If you spot an error that warrants correction, please contact the editor at [email protected]. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned.
We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Thank you for reading.
